company background image
GX1

genXone WSE:GX1 Stock Report

Last Price

zł14.92

Market Cap

zł49.2m

7D

-0.3%

1Y

-38.9%

Updated

28 May, 2022

Data

Company Financials
GX1 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends3/6

GX1 Stock Overview

genXone S.A. develops products and solutions based on nucleic acid sequencing technologies in Poland and internationally.

genXone Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for genXone
Historical stock prices
Current Share Pricezł14.92
52 Week Highzł34.50
52 Week Lowzł13.02
Beta0
1 Month Change-10.66%
3 Month Change-3.12%
1 Year Change-38.85%
3 Year Changen/a
5 Year Changen/a
Change since IPO-65.30%

Recent News & Updates

Dec 06
Investors Holding Back On genXone S.A. (WSE:GX1)

Investors Holding Back On genXone S.A. (WSE:GX1)

With a price-to-earnings (or "P/E") ratio of 8.6x genXone S.A. ( WSE:GX1 ) may be sending bullish signals at the...

Shareholder Returns

GX1PL BiotechsPL Market
7D-0.3%-2.3%1.3%
1Y-38.9%-41.8%-17.1%

Return vs Industry: GX1 exceeded the Polish Biotechs industry which returned -41.8% over the past year.

Return vs Market: GX1 underperformed the Polish Market which returned -17.1% over the past year.

Price Volatility

Is GX1's price volatile compared to industry and market?
GX1 volatility
GX1 Average Weekly Movement7.1%
Biotechs Industry Average Movement7.0%
Market Average Movement6.8%
10% most volatile stocks in PL Market13.6%
10% least volatile stocks in PL Market4.5%

Stable Share Price: GX1 is not significantly more volatile than the rest of Polish stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: GX1's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a21Michal Kaszubahttps://www.genxone.eu

genXone S.A. develops products and solutions based on nucleic acid sequencing technologies in Poland and internationally. The company specializes in next generation sequencing and medical diagnostics. It uses nanopore sequencing technology in the areas of science, business, and medicine; and specializes in the field of microbiome research, multi-genetic diseases, RNA, genomics, metagenomics, transcriptomics of bacteriophages, nutrigenomics, genetics of metabolic diseases, molecular ecology, and genetic engineering and bioinformatics.

genXone Fundamentals Summary

How do genXone's earnings and revenue compare to its market cap?
GX1 fundamental statistics
Market Capzł49.16m
Earnings (TTM)zł8.65m
Revenue (TTM)zł25.19m

5.7x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GX1 income statement (TTM)
Revenuezł25.19m
Cost of Revenuezł9.21m
Gross Profitzł15.98m
Other Expenseszł7.33m
Earningszł8.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 12, 2022

Earnings per share (EPS)2.62
Gross Margin63.43%
Net Profit Margin34.34%
Debt/Equity Ratio0.0%

How did GX1 perform over the long term?

See historical performance and comparison

Dividends

6.7%

Current Dividend Yield

38%

Payout Ratio

Does GX1 pay a reliable dividends?

See GX1 dividend history and benchmarks
When do you need to buy GX1 by to receive an upcoming dividend?
genXone dividend dates
Ex Dividend DateJun 17 2022
Dividend Pay DateJul 04 2022
Days until Ex dividend19 days
Days until Dividend pay date36 days

Does GX1 pay a reliable dividends?

See GX1 dividend history and benchmarks

Valuation

Is genXone undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: GX1 (PLN14.92) is trading below our estimate of fair value (PLN222.17)

Significantly Below Fair Value: GX1 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GX1 is good value based on its Price-To-Earnings Ratio (5.7x) compared to the Polish Biotechs industry average (34.9x).

PE vs Market: GX1 is good value based on its Price-To-Earnings Ratio (5.7x) compared to the Polish market (10x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GX1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GX1 is good value based on its Price-To-Book Ratio (2.1x) compared to the PL Biotechs industry average (3.8x).


Future Growth

How is genXone forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


42.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as genXone has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has genXone performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


81.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: GX1 has high quality earnings.

Growing Profit Margin: GX1's current net profit margins (34.3%) are lower than last year (35.6%).


Past Earnings Growth Analysis

Earnings Trend: GX1's earnings have grown significantly by 81.1% per year over the past 5 years.

Accelerating Growth: GX1's earnings growth over the past year (5.1%) is below its 5-year average (81.1% per year).

Earnings vs Industry: GX1 earnings growth over the past year (5.1%) exceeded the Biotechs industry -6.2%.


Return on Equity

High ROE: GX1's Return on Equity (36.9%) is considered high.


Financial Health

How is genXone's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: GX1's short term assets (PLN19.0M) exceed its short term liabilities (PLN3.4M).

Long Term Liabilities: GX1's short term assets (PLN19.0M) exceed its long term liabilities (PLN104.4K).


Debt to Equity History and Analysis

Debt Level: GX1 is debt free.

Reducing Debt: GX1 had no debt 5 years ago.

Debt Coverage: GX1 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GX1 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is genXone current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


6.70%

Current Dividend Yield

Upcoming Dividend Payment

TodayMay 28 2022Ex Dividend DateJun 17 2022Dividend Pay DateJul 04 202217 days from Ex DividendBuy in the next 19 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: GX1's dividend (6.7%) is higher than the bottom 25% of dividend payers in the Polish market (2.63%).

High Dividend: GX1's dividend (6.7%) is low compared to the top 25% of dividend payers in the Polish market (7.73%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether GX1's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if GX1's dividend payments are increasing as they only just started paying a dividend.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (38.1%), GX1's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (29.8%), GX1's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Michal Kaszuba

no data

Tenure

Dr. Michal Kaszuba is President of the Board at genXone S.A. He is the main originator, co-founder of the genXone S.A. He is a graduate of the University of Warmia and Mazury in Olsztyn (Faculty of Biology...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

genXone S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: genXone S.A.
  • Ticker: GX1
  • Exchange: WSE
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: zł49.161m
  • Shares outstanding: 3.30m
  • Website: https://www.genxone.eu

Number of Employees


Location

  • genXone S.A.
  • ul. Kobaltowa 6
  • Zlotniki
  • Suchy Las
  • 60-002
  • Poland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.